Matthew A. Nehs
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Matthew A. Nehs has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
- Justine A. Barletta
Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
33 shared publications - Erik K. Alexander
Brigham Education Institute Brigham and Women's Hospital Boston Massachusetts USA
31 shared publications - Ellen Marqusee
From the Division of Neuroradiology (JPG, MM), Department of Radiology (VL), and Division of Endocrinology, Diabetes and Hypertension (EM, MIK), Brigham and Women’s Hospital, Boston, MA, USA. From the Warren Alpert Medical School of Brown University (MM), Providence, RI, USA
27 shared publications - Kristine Wong
Department of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts
27 shared publications - Nancy L. Cho
Harvard Medical School, Boston, Massachusetts
27 shared publications - Athanasios Bikas
Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital and Harvard Medical School , Boston, MA 02115
26 shared publications
Latest Publications
- 7 February 2026
- Published by Elsevier in The American Journal of Surgery
- Vol. 255, 116851
Going back to the back: Insights on reoperative adrenalectomy
- 7 February 2026
- Published by Elsevier in The American Journal of Surgery
- Vol. 255, 116851
Going back to the back: Insights on reoperative adrenalectomy
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Additional Oncogenic Alterations in RAS-Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes
Supplementary Table S2. Characteristics of patients with RAS-mutant anaplastic thyroid cancer
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Additional Oncogenic Alterations in RAS-Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes
Supplementary Table S2. Characteristics of patients with RAS-mutant anaplastic thyroid cancer
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Additional Oncogenic Alterations in RAS-Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes
Supplementary Table S1. List of all variants detected by Oncopanel in 78 RAS-mutant thyroid tumors
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Additional Oncogenic Alterations in RAS-Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes
Supplementary Table S1. List of all variants detected by Oncopanel in 78 RAS-mutant thyroid tumors
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Additional Oncogenic Alterations in RAS-Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes
Supplementary Table S3. Comparison of clinical and pathologic characteristics of differentiated thyroid cancers with diploid versus heterozygous losses at chromosome 22q
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Additional Oncogenic Alterations in RAS-Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes
Supplementary Table S3. Comparison of clinical and pathologic characteristics of differentiated thyroid cancers with diploid versus heterozygous losses at chromosome 22q
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Additional Oncogenic Alterations in RAS-Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes
Purpose:RAS mutations occur across the spectrum of thyroid neoplasms, and more tools are needed for better prognostication. The objective of this study was to evaluate how additional genetic events affecting key genes modify prognosis in patients with RAS-mutant thyroid cancers, and specifically differentiated thyroid cancers (DTC).Experimental Design:We performed a clinical–genomic analysis of consecutive patients with DTC, poorly differentiated (PDTC), or anaplastic thyroid cancer (ATC) between January 2014 and December 2021, in whom a custom-targeted next-generation sequencing assay was performed. Patients harboring RAS mutations were included, and we compared their clinical features and outcomes based upon the presence of additional oncogenic alterations.Results:Seventy-eight patients were identified, with 22% (17/78) harboring a driver RAS mutation plus an additional oncogenic alteration. All six (100%) ATCs had an additional mutation. Compared with DTCs harboring a solitary RAS mutation, patients with DTC with RAS and additional mutation(s) were more likely to be classified as American Thyroid Association high-risk of recurrence (77% vs. 12%; P < 0.001) and to have larger primary tumors (4.7 vs. 2.5 cm; P = 0.002) and advanced stage (III or IV) at presentation (67% vs. 3%; P < 0.001). Importantly, over an average 65-month follow-up, DTC-specific-mortality was more than 10-fold higher (20% vs. 1.8%; P = 0.011) when additional mutations were identified.Conclusions:Identification of key additional mutations in patients with RAS-mutant thyroid cancers confers a more aggressive phenotype, increases mortality risk in DTC, and can explain the diversity of RAS-mutated thyroid neoplasia. These data support genomic profiling of DTCs to inform prognosis and clinical decision-making.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Additional Oncogenic Alterations in RAS-Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes
Purpose:RAS mutations occur across the spectrum of thyroid neoplasms, and more tools are needed for better prognostication. The objective of this study was to evaluate how additional genetic events affecting key genes modify prognosis in patients with RAS-mutant thyroid cancers, and specifically differentiated thyroid cancers (DTC).Experimental Design:We performed a clinical–genomic analysis of consecutive patients with DTC, poorly differentiated (PDTC), or anaplastic thyroid cancer (ATC) between January 2014 and December 2021, in whom a custom-targeted next-generation sequencing assay was performed. Patients harboring RAS mutations were included, and we compared their clinical features and outcomes based upon the presence of additional oncogenic alterations.Results:Seventy-eight patients were identified, with 22% (17/78) harboring a driver RAS mutation plus an additional oncogenic alteration. All six (100%) ATCs had an additional mutation. Compared with DTCs harboring a solitary RAS mutation, patients with DTC with RAS and additional mutation(s) were more likely to be classified as American Thyroid Association high-risk of recurrence (77% vs. 12%; P < 0.001) and to have larger primary tumors (4.7 vs. 2.5 cm; P = 0.002) and advanced stage (III or IV) at presentation (67% vs. 3%; P < 0.001). Importantly, over an average 65-month follow-up, DTC-specific-mortality was more than 10-fold higher (20% vs. 1.8%; P = 0.011) when additional mutations were identified.Conclusions:Identification of key additional mutations in patients with RAS-mutant thyroid cancers confers a more aggressive phenotype, increases mortality risk in DTC, and can explain the diversity of RAS-mutated thyroid neoplasia. These data support genomic profiling of DTCs to inform prognosis and clinical decision-making.
- 1 January 2025
- Published by Springer Nature
- p. 307-319
Lateral Transabdominal Adrenalectomy Versus Posterior Retroperitoneal Adrenalectomy
- 1 January 2025
- Published by Springer Nature
- p. 307-319
Lateral Transabdominal Adrenalectomy Versus Posterior Retroperitoneal Adrenalectomy
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Additional Oncogenic Alterations in RAS-Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes
Supplementary Table S3. Comparison of clinical and pathologic characteristics of differentiated thyroid cancers with diploid versus heterozygous losses at chromosome 22q
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Additional Oncogenic Alterations in RAS-Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes
Supplementary Table S3. Comparison of clinical and pathologic characteristics of differentiated thyroid cancers with diploid versus heterozygous losses at chromosome 22q
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Additional Oncogenic Alterations in RAS-Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes
Supplementary Table S1. List of all variants detected by Oncopanel in 78 RAS-mutant thyroid tumors
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Additional Oncogenic Alterations in RAS-Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes
Supplementary Table S1. List of all variants detected by Oncopanel in 78 RAS-mutant thyroid tumors
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Data from Additional Oncogenic Alterations in RAS-Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes
Purpose: RAS mutations occur across the spectrum of thyroid neoplasms, and more tools are needed for better prognostication. The objective of this study was to evaluate how additional genetic events affecting key genes modify prognosis in patients with RAS-mutant thyroid cancers, and specifically differentiated thyroid cancers (DTC). Experimental Design: We performed a clinical–genomic analysis of consecutive patients with DTC, poorly differentiated (PDTC), or anaplastic thyroid cancer (ATC) between January 2014 and December 2021, in whom a custom-targeted next generation sequencing assay was performed. Patients harboring RAS mutations were included, and we compared their clinical features and outcomes based upon the presence of additional oncogenic alterations. Results: Seventy-eight patients were identified, with 22% (17/78) harboring a driver RAS mutation plus an additional oncogenic alteration. All six (100%) ATCs had an additional mutation. Compared to DTCs harboring a solitary RAS mutation, DTC patients with RAS and additional mutation(s) were more likely to be classified as American Thyroid Association high-risk of recurrence (77% vs. 12%; P<0.001), have larger primary tumors (4.7 vs. 2.5 cm; P=0.002) and advanced stage (III or IV) at presentation (67% vs. 3%; P<0.001). Importantly, over an average 65-month follow-up, DTC-specific-mortality was more than 10-fold higher (20% vs. 1.8%, P=0.011) when additional mutations were identified. Conclusions: Identification of key additional mutations in patients with RAS-mutant thyroid cancers confers a more aggressive phenotype, increases mortality risk in DTC, and can explain the diversity of RAS-mutated thyroid neoplasia. These data support genomic profiling of DTCs to inform prognosis and clinical decision making.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Additional Oncogenic Alterations in RAS-Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes
Purpose: RAS mutations occur across the spectrum of thyroid neoplasms, and more tools are needed for better prognostication. The objective of this study was to evaluate how additional genetic events affecting key genes modify prognosis in patients with RAS-mutant thyroid cancers, and specifically differentiated thyroid cancers (DTC). Experimental Design: We performed a clinical–genomic analysis of consecutive patients with DTC, poorly differentiated (PDTC), or anaplastic thyroid cancer (ATC) between January 2014 and December 2021, in whom a custom-targeted next generation sequencing assay was performed. Patients harboring RAS mutations were included, and we compared their clinical features and outcomes based upon the presence of additional oncogenic alterations. Results: Seventy-eight patients were identified, with 22% (17/78) harboring a driver RAS mutation plus an additional oncogenic alteration. All six (100%) ATCs had an additional mutation. Compared to DTCs harboring a solitary RAS mutation, DTC patients with RAS and additional mutation(s) were more likely to be classified as American Thyroid Association high-risk of recurrence (77% vs. 12%; P<0.001), have larger primary tumors (4.7 vs. 2.5 cm; P=0.002) and advanced stage (III or IV) at presentation (67% vs. 3%; P<0.001). Importantly, over an average 65-month follow-up, DTC-specific-mortality was more than 10-fold higher (20% vs. 1.8%, P=0.011) when additional mutations were identified. Conclusions: Identification of key additional mutations in patients with RAS-mutant thyroid cancers confers a more aggressive phenotype, increases mortality risk in DTC, and can explain the diversity of RAS-mutated thyroid neoplasia. These data support genomic profiling of DTCs to inform prognosis and clinical decision making.